Application of Next Generation Sequencing in Laboratory Medicine
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
The rapid development of next-generation sequencing (NGS) technology, including advances in sequencing chemistry, sequencing technologies, bioinformatics, and data interpretation, has facilitated its wide clinical application in precision medicine. This review describes current sequencing technologies, including short- and long-read sequencing technologies, and highlights the clinical application of NGS in inherited diseases, oncology, and infectious diseases. We review NGS approaches and clinical diagnosis for constitutional disorders; summarize the application of U.S. Food and Drug Administration-approved NGS panels, cancer biomarkers, minimal residual disease, and liquid biopsy in clinical oncology; and consider epidemiological surveillance, identification of pathogens, and the importance of host microbiome in infectious diseases. Finally, we discuss the challenges and future perspectives of clinical NGS tests.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
RNA-Seq: a revolutionary tool for transcriptomics
Wang, Z., Gerstein, M., & Snyder, M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2484 · Cited by 13,174 · cited 1×
“Illumina platforms are currently widely used in the NGS field [37-43].”
MethodSequencing technologies – the next generation
Metzker, M. L. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2626 · Cited by 7,066 · cited 1×
“In the presence of ATP, luciferase coverts luciferin to oxyluciferin to generate light, which is then detected and captured by a coupled-charge device (CCD) camera [28-30].”
MethodComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Coming of age: ten years of next-generation sequencing technologies
Goodwin, S., McPherson, J. D., & McCombie, W. R. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.49 · Cited by 4,352
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · cited 1×
“NPM1 is the most frequently mutated gene in adult type AML, and NPM1 mutations are associated with favorable outcomes in the absence of concurrent DNTM3A and FLT3-ITD mutations [106].”
BackgroundReal-Time DNA Sequencing from Single Polymerase Molecules
Eid, J., Fehr, A., Gray, J., Luong, K., Lyle, J., Otto, G., Peluso, P., Rank, D., Baybayan, P., Bettman, B., et al. (2009) · Science · doi:10.1126/science.1162986 · Cited by 3,732
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Accurate whole human genome sequencing using reversible terminator chemistry
Bentley, D. R., Balasubramanian, S., Swerdlow, H. P., Smith, G. P., Milton, J., Brown, C. G., Hall, K. P., Evers, D. J., Barnes, C. L., Bignell, H. R., et al. (2008) · Nature · doi:10.1038/nature07517 · Cited by 3,684
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Miller, D. T., Adam, M. P., Aradhya, S., Biesecker, L. G., Brothman, A. R., Carter, N. P., Church, D. M., Crolla, J. A., Eichler, E. E., Epstein, C. J., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.04.006 · Cited by 2,882 · cited 2×
“High-resolution chromosomal microarray analysis (CMA) detects gene copy number variations (CNVs) and has a diagnostic yield of 15-20% for the same disease categories [60].”
BackgroundEfficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase
Sanger, F., & Coulson, A. R. (1975) · Journal of Molecular Biology · doi:10.1016/0022-2836(75)90213-2 · Cited by 2,709 · cited 1×
“The first-generation platform, Sanger sequencing, was developed by Fred Sanger in 1977 and has been used for decades in research and clinical genetics [14-16].”
MethodDevelopment of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683
Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.022 · Cited by 2,546 · cited 2×
“Recently, the US FDA issued draft guidelines on the use of MRD assessment in trials involving patients with hematologic malignancies [6].”
BackgroundScreening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 1×
“The US FDA approved Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) panel, developed by the Memorial Sloan Kettering Cancer Center, and the FoundationOne CDx (F1CDx), developed by Foundation Medicine, for in vitro diagnosis via detection of genetic variants in November…”
MethodMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079 · cited 1×
“MSI-H or dMMR metastatic colorectal cancer [128, 129].”
Quail, M., Smith, M. E., Coupland, P., Otto, T. D., Harris, S. R., Connor, T. R., Bertoni, A., Swerdlow, H. P., & Gu, Y. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-341 · Cited by 2,031 · cited 1×
“nologies, could address some of these issues [55-59].”
BackgroundDNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964 · cited 1×
“ROS1 mutations are present in 1-2% of NSCLC patients who may be sensitive to crizotinib and entrectinib, approved by the US FDA in 2016 and 2019, respectively [122, 123].”
BackgroundDoebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776 · cited 9×
“prognosis in cytogenetically normal AML [112-114]; however, patients with TET2 mutations may respond to hypomethylating agents [115].”
BackgroundInfluentialLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Current and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
Molecular Findings Among Patients Referred for Clinical Whole-Exome Sequencing
Yang, Y., Muzny, D. M., Xia, F., Niu, Z., Person, R., Ding, Y., Ward, P., Braxton, A., Wang, M., Buhay, C., et al. (2014) · JAMA · doi:10.1001/jama.2014.14601 · Cited by 1,360
Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4070 · Cited by 1,176 · cited 1×
“fied as MSI-high (MSI-H) or MMR deficient (dMMR) [127].”
BackgroundNext-generation DNA sequencing techniques
Ansorge, W. J. (2009) · New Biotechnology · doi:10.1016/j.nbt.2008.12.009 · Cited by 993 · cited 1×
“In the presence of ATP, luciferase coverts luciferin to oxyluciferin to generate light, which is then detected and captured by a coupled-charge device (CCD) camera [28-30].”
MethodActionable Diagnosis of Neuroleptospirosis by Next-Generation Sequencing
Wilson, M. R., Naccache, S. N., Samayoa, E., Biagtan, M., Bashir, H., Yu, G., Salamat, S. M., Somasekar, S., Federman, S., Miller, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401268 · Cited by 977
Blauwkamp, T. A., Thair, S., Rosen, M. J., Blair, L., Lindner, M. S., Vilfan, I. D., Kawli, T., Christians, F. C., Venkatasubrahmanyam, S., Wall, G. D., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-018-0349-6 · Cited by 962
Snitkin, E. S., Zelazny, A. M., Thomas, P. J., Stock, F., Program, N. C. S., Henderson, D. K., Palmore, T. N., & Segre, J. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004129 · Cited by 863
Zhao, P., Li, L., Jiang, X., & Li, Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0738-1 · Cited by 682
Leber, A. L., Everhart, K., Balada-Llasat, J.-M., Cullison, J., Daly, J., Holt, S., Lephart, P., Salimnia, H., Schreckenberger, P. C., DesJarlais, S., et al. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.00730-16 · Cited by 609
Ellington, M. J., Ekelund, O., Aarestrup, F. M., Canton, R., Doumith, M., Giske, C., Grundman, H., Hasman, H., Holden, M. T. G., Hopkins, K. L., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.11.012 · Cited by 603
Decade-long bacterial community dynamics in cystic fibrosis airways
Zhao, J., Schloss, P. D., Kalikin, L. M., Carmody, L. A., Foster, B. K., Petrosino, J. F., Cavalcoli, J. D., VanDevanter, D. R., Murray, S., Li, J. Z., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120577109 · Cited by 599
Miller, S., Naccache, S., Samayoa, E., Messacar, K., Arevalo, S., Federman, S., Stryke, D., Pham, E., Fung, B., Bolosky, W., et al. (2018) · doi:10.1101/330381 · Cited by 583
Shaw, A. T., Riely, G. J., Bang, Y.-J., Kim, D.-W., Camidge, D. R., Solomon, B. J., Varella-Garcia, M., Iafrate, A. J., Shapiro, G. I., Usari, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz131 · Cited by 576
Buss, S. N., Leber, A., Chapin, K., Fey, P. D., Bankowski, M. J., Jones, M. K., Rogatcheva, M., Kanack, K. J., & Bourzac, K. M. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.02674-14 · Cited by 554
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Metzeler, K. H., Herold, T., Rothenberg-Thurley, M., Amler, S., Sauerland, M. C., Görlich, D., Schneider, S., Konstandin, N. P., Dufour, A., Bräundl, K., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693879 · Cited by 529
Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing
The CRyPTIC Consortium and the 100, 0. G. P. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800474 · Cited by 500
Temporal Response of the Human Virome to Immunosuppression and Antiviral Therapy
De Vlaminck, I., Khush, K. K., Strehl, C., Kohli, B., Luikart, H., Neff, N. F., Okamoto, J., Snyder, T. M., Cornfield, D. N., Nicolls, M. R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.10.034 · Cited by 471
Rapid whole-genome sequencing decreases infant morbidity and cost of hospitalization
Farnaes, L., Hildreth, A., Sweeney, N. M., Clark, M. M., Chowdhury, S., Nahas, S., Cakici, J. A., Benson, W., Kaplan, R. H., Kronick, R., et al. (2018) · npj Genomic Medicine · doi:10.1038/s41525-018-0049-4 · Cited by 445 · cited 1×
“results reduced inpatient cost by $800,000-2,000,000 [86].”
Hasan, M. R., Rawat, A., Tang, P., Jithesh, P. V., Thomas, E., Tan, R., & Tilley, P. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.03050-15 · Cited by 243
Clark, T. A., Chung, J. H., Kennedy, M., Hughes, J. D., Chennagiri, N., Lieber, D. S., Fendler, B., Young, L., Zhao, M., Coyne, M., et al. (2018) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.05.004 · Cited by 200
Sequence Analysis of the Human Virome in Febrile and Afebrile Children
Wylie, K. M., Mihindukulasuriya, K. A., Sodergren, E., Weinstock, G. M., & Storch, G. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0027735 · Cited by 193
Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
Chin, R.-I., Chen, K., Usmani, A., Chua, C., Harris, P. K., Binkley, M. S., Azad, T. D., Dudley, J. C., & Chaudhuri, A. A. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00390-5 · Cited by 191
Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract
Burnham, P., Dadhania, D., Heyang, M., Chen, F., Westblade, L. F., Suthanthiran, M., Lee, J. R., & De Vlaminck, I. (2018) · Nature Communications · doi:10.1038/s41467-018-04745-0 · Cited by 160
Brown, S. D., Nagaraju, S., Utturkar, S., De Tissera, S., Segovia, S., Mitchell, W., Land, M. L., Dassanayake, A., & Köpke, M. (2014) · Biotechnology for Biofuels · doi:10.1186/1754-6834-7-40 · Cited by 145 · cited 1×
“nologies, could address some of these issues [55-59].”
BackgroundWeirather, J. L., Afshar, P. T., Clark, T. A., Tseng, E., Powers, L. S., Underwood, J. G., Zabner, J., Korlach, J., Wong, W. H., & Au, K. F. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv562 · Cited by 123
Cited by
Network approach in liquidomics landscape
Santini, D., Botticelli, A., Galvano, A., Iuliani, M., Incorvaia, L., Gristina, V., Taffon, C., Foderaro, S., Paccagnella, E., Simonetti, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02743-9 · Cited by 37
MutationExplorer : a webserver for mutation of proteins and 3D visualization of energetic impacts
Philipp, M., Moth, C. W., Ristic, N., Tiemann, J. K. S., Seufert, F., Panfilova, A., Meiler, J., Hildebrand, P. W., Stein, A., Wiegreffe, D., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae301 · Cited by 35
Metadata
- Authors
- Zhong, Y., Xu, F., Wu, J., Schubert, J., & Li, M. M.
- Venue
- Annals of Laboratory Medicine
- Publisher
- Annals of Laboratory Medicine
- Published
- 2021-01-01
- Volume
- 41
- Issue
- 1
- Pages
- 25-43
- ISSN
- 2234-3806 (ISSN-L)
- 2234-3814
- OpenAlex
- W3081205391
- Cited by
- 215
- References
- 51
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.